Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818283 | 0.81 | GSK3B (0.57) | GSK3BPTPN1 | |
| SCHEMBL14531325 | 0.77 | GSK3B (0.42) | GSK3BPTPN1ANPEPENPEP | |
| SCHEMBL20221599 | 0.77 | ESR1 (0.55) | GSK3BPTPN1 | |
| SCHEMBL3222270 | 0.76 | GSK3B (0.44) | GSK3BPTPN1ANPEPENPEP | |
| SCHEMBL13643091 | 0.76 | GSK3B (0.38) | GSK3BPTPN1 | |
| SCHEMBL13643094 | 0.75 | ACACB (0.41) | — | |
| SCHEMBL5728691 | 0.75 | ACACB (0.41) | — | |
| SCHEMBL6140804 | 0.75 | GSK3B (0.53) | GSK3BPTPN1 | |
| SCHEMBL13643238 | 0.74 | GSK3B (0.53) | GSK3BPTPN1 | |
| SCHEMBL8611695 | 0.74 | CYP4A11 (0.56) | GSK3BPTPN1CYP4A11CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | GSK3B 1763/4885PTPN1 3710/4885CYP4A11 4619/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | GSK3B 1323/4885PTPN1 3910/4885CYP4A11 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.